Hyderabad, Telangana, India, November 2025 – Kshitiz Gadodia has stepped into his new role as President – Finance & Global CFO at Hetero, marking a significant milestone in his distinguished career in pharmaceutical finance and global business leadership. With deep experience across financial strategy, operational governance and business partnering, he now joins Hetero at a pivotal moment as the company accelerates its global growth and transformation agenda.
In his most recent role as Chief Financial Officer at Intas Pharmaceuticals, he led large-scale financial operations, guided enterprise-wide performance initiatives and strengthened decision-making frameworks across the organisation. His tenure at Intas further honed his capabilities in commercial finance, business partnering and financial governance within a fast-growing global pharmaceutical environment.
Before Intas, he served as Vice President – Business Finance Group at Lupin, where he oversaw business finance, commercial performance and financial planning across multiple markets. At Novartis, he headed Global BPA Finance (Manufacturing Operations), contributing to global operational excellence and driving finance-led improvements in manufacturing performance.
Earlier in his career, Kshitiz spent over nine years with Dr. Reddy’s Laboratories in roles such as Senior Director Finance, Director Finance, and Associate Director Finance, where he contributed to strategic finance, performance optimisation and cross-functional transformation. His leadership foundations were built through impactful financial roles at Shell and the Tolaram Group, shaping his global perspective across finance operations, controls, compliance and business management.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. With more than 30 years of expertise, Hetero operates across strategic business areas including APIs, generics, biosimilars, custom pharmaceutical services and branded generics. Its strong global footprint spans 145+ countries, supported by 36+ state-of-the-art manufacturing facilities approved by major global regulatory authorities.
The company’s diverse portfolio of 400+ products covers key therapeutic areas such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology. Committed to affordability and access, Hetero continues to drive innovation, expand global impact and enhance patient care worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
